GR3035941T3 - Vaccine adjuvants - Google Patents

Vaccine adjuvants

Info

Publication number
GR3035941T3
GR3035941T3 GR20010400796T GR20010400796T GR3035941T3 GR 3035941 T3 GR3035941 T3 GR 3035941T3 GR 20010400796 T GR20010400796 T GR 20010400796T GR 20010400796 T GR20010400796 T GR 20010400796T GR 3035941 T3 GR3035941 T3 GR 3035941T3
Authority
GR
Greece
Prior art keywords
adjuvants
vaccine
vaccine adjuvants
sulpholipid
polysaccharide
Prior art date
Application number
GR20010400796T
Other languages
English (en)
Inventor
Luuk Hilgers
Original Assignee
Dimminaco Ag Sa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3888560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3035941(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dimminaco Ag Sa Ltd filed Critical Dimminaco Ag Sa Ltd
Publication of GR3035941T3 publication Critical patent/GR3035941T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR20010400796T 1994-12-27 2001-05-28 Vaccine adjuvants GR3035941T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9401174A BE1008978A5 (fr) 1994-12-27 1994-12-27 Adjuvants pour vaccins.
PCT/BE1995/000119 WO1996020008A1 (fr) 1994-12-27 1995-12-21 Adjuvants pour vaccins

Publications (1)

Publication Number Publication Date
GR3035941T3 true GR3035941T3 (en) 2001-08-31

Family

ID=3888560

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400796T GR3035941T3 (en) 1994-12-27 2001-05-28 Vaccine adjuvants

Country Status (17)

Country Link
US (2) US6165995A (el)
EP (2) EP0800539B1 (el)
JP (2) JP4087900B2 (el)
CN (2) CN1132630C (el)
AT (2) ATE248863T1 (el)
AU (2) AU713997B2 (el)
BE (1) BE1008978A5 (el)
BR (2) BR9510223A (el)
CA (2) CA2208790C (el)
DE (2) DE69520376T2 (el)
DK (2) DK0814836T3 (el)
ES (2) ES2204969T3 (el)
GR (1) GR3035941T3 (el)
MX (1) MX9704822A (el)
PT (2) PT800539E (el)
SI (1) SI0800539T1 (el)
WO (2) WO1996020222A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
ES2500490T3 (es) * 1997-08-29 2014-09-30 Antigenics Inc. Composiciones que comprenden el adyuvante QS-21 y polisorbato o ciclodextrina como excipiente
EP1104767A1 (en) * 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
AT408150B (de) * 2000-04-14 2001-09-25 Oesterr Forsch Seibersdorf Verfahren zur immobilisierung eines analyten an einer festen oberfläche
FR2808691B1 (fr) * 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
FR2825714B1 (fr) * 2001-06-08 2005-03-25 Seppic Sa Nouvelle utilisation de complexes d'inclusion de cyclodestrine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003220685A1 (en) * 2002-04-09 2003-10-27 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
EP2591786B1 (en) * 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
NZ592293A (en) 2005-11-28 2012-10-26 Verrow Pharmaceuticals Inc Compositions comprising an oligosaccharide such as a cyclodextrin for reducing the nephrotoxicity of other drugs
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
RU2489164C9 (ru) * 2007-11-06 2014-01-20 ВАЙЕТ ЭлЭлСи АВИРУЛЕНТНАЯ АДЪЮВАНТНАЯ ЖИВАЯ ВАКЦИНА ПРОТИВ Mycoplasma hyopneumoniae
EP2062594A1 (en) * 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
US9125951B2 (en) 2009-06-22 2015-09-08 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
EP2397484A1 (en) 2010-06-11 2011-12-21 Immunovo B.V. Trisaccharide derivates, and their use as adjuvants
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
CN101972477B (zh) * 2010-10-21 2012-09-26 中国医学科学院医学生物学研究所 磷酸锌疫苗佐剂
CA2819120C (en) 2010-12-22 2016-07-05 Wyeth Llc Stable immunogenic compositions of staphylococcus aureus antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
HRP20221438T1 (hr) 2012-12-20 2023-02-03 Pfizer Inc. Postupak glikokonjugiranja
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102319843B1 (ko) 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
CN104086676B (zh) * 2014-07-18 2017-01-25 江苏省农业科学院 一种环糊精酯化衍生物、制备方法及其应用
EP3193923B1 (en) * 2014-07-24 2019-09-18 Litevax B.V. Adjuvants
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3292146A1 (en) 2015-05-04 2018-03-14 Pfizer Inc Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN106928378A (zh) * 2017-03-29 2017-07-07 中国药科大学 一种十二酰基‑β‑环糊精的制备方法和用于色氨酸手性拆分的聚砜膜的制备方法
BR112020017715A2 (pt) 2018-03-16 2020-12-29 Zoetis Services Llc Vacinas de peptídeo contra interleucina-31
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565887A (en) * 1968-05-15 1971-02-23 Corn Products Co Unsaturated and long chain esters of cyclodextrin
US4247535A (en) * 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5760015A (en) * 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
WO1991013100A1 (en) * 1990-03-02 1991-09-05 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
FR2672496B3 (fr) * 1990-07-18 1993-05-28 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
IT1242214B (it) * 1990-11-13 1994-03-03 Emo Chiellini Derivati polifunzionali delle ciclodestrine
JP2556236B2 (ja) * 1991-08-29 1996-11-20 田辺製薬株式会社 β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
CA2085827C (en) * 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
DE4220734A1 (de) * 1992-06-25 1994-01-05 Puetter Medice Chem Pharm Lipophile Cyclodextrinpolymere
US5464827A (en) * 1994-06-20 1995-11-07 American Home Products Corporation Esterified polyanionic cyclodextrins as smooth muscle cell proliferation inhibitors
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.

Also Published As

Publication number Publication date
CN1132630C (zh) 2003-12-31
EP0800539B1 (en) 2003-09-03
US6328965B1 (en) 2001-12-11
DE69520376D1 (de) 2001-04-19
DK0800539T3 (da) 2003-12-08
BR9510223A (pt) 1997-12-30
JPH10511997A (ja) 1998-11-17
EP0814836B1 (fr) 2001-03-14
WO1996020222A1 (en) 1996-07-04
DE69531699D1 (de) 2003-10-09
JPH11502192A (ja) 1999-02-23
EP0814836A1 (fr) 1998-01-07
DE69520376T2 (de) 2001-08-09
PT800539E (pt) 2004-01-30
MX9704822A (es) 1998-05-31
CN1109049C (zh) 2003-05-21
ATE199644T1 (de) 2001-03-15
JP3927235B2 (ja) 2007-06-06
ES2204969T3 (es) 2004-05-01
AU713997B2 (en) 1999-12-16
WO1996020008A1 (fr) 1996-07-04
CA2208849C (en) 2006-10-10
JP4087900B2 (ja) 2008-05-21
DK0814836T3 (da) 2001-04-17
ES2155540T3 (es) 2001-05-16
CN1171052A (zh) 1998-01-21
ATE248863T1 (de) 2003-09-15
BR9510263A (pt) 1997-11-04
AU4324896A (en) 1996-07-19
CA2208849A1 (en) 1996-07-04
US6165995A (en) 2000-12-26
AU709104B2 (en) 1999-08-19
CA2208790C (en) 2012-01-31
MX9704824A (es) 1998-06-30
CN1175264A (zh) 1998-03-04
CA2208790A1 (en) 1996-07-04
SI0800539T1 (en) 2003-12-31
EP0800539A1 (en) 1997-10-15
BE1008978A5 (fr) 1996-10-01
PT814836E (pt) 2001-07-31
DE69531699T2 (de) 2004-07-08
AU4324996A (en) 1996-07-19

Similar Documents

Publication Publication Date Title
GR3035941T3 (en) Vaccine adjuvants
ATE410183T1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
DE69529684T2 (de) Adjuvans für impfstoff
MY129994A (en) Novel siloxane derivatives, producing method thereof and agents including siloxane derivative
BG101995A (en) Saponin and sterol-containing vaccines
ATE196737T1 (de) Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
GB9817052D0 (en) Vaccine
DK55891A (da) Matrix med immunomodulerende virkning
BR9106205A (pt) Dispositivo para implantacao em hospedeiro,processo de implantacao,dispositivo implantado,e recipiente de imunoisolamento
NO306905B1 (no) Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen
ES2044849T3 (es) Un procedimiento para preparar un glicosido de flavona.
OA09800A (en) Vaccine compositions containing liposomes.
NL300404I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
FI98510B (fi) Vateriitti ja menetelmä sen valmistamiseksi
PT876398E (pt) Inducao de respostas imunitarias contra determinantes desejados
EP0651609A4 (en) VACCINES AGAINST ANATOXIN PASTEURELLA MULTOCIDA.
CA2090701A1 (en) Solubilization of proteins in active forms
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
GR3019525T3 (en) Neuraminidase and galactose oxidase as vaccine adjuvant
GB9303681D0 (en) Vaccines